What's In Store from Congress?

Now that the elections are over, the pharmaceutical industry is left to ponder what the new Congress has in store for it. There has already been a lot of speculation in the general press and trade media as well as some shots fired across the bow by Congress.

It's not just democrats itching to get at Pharma. For example, the Senate Committee on Health, Education, Labor, and Pensions (HELP) chaired by Sen. Michael B. Enzi (R-Wyoming), met in full session on November 16, 2006 ("Hearing on Building a 21st Century FDA: Proposals to Improve Drug Safety and Innovation") and Senator Charles Grassley (R-Iowa) has put a hold on the nomination of Dr. Andrew C. von Eschenbach for commissioner of the FDA.

Today's post to Pharma Marketing Blog provides you with a synopsis of the major issues, an invitation to take an online survey for your predictions/expectations, highlights from testimony by J&J and Consumers' Union, and links to resources.

For more on this, see today's post to Pharma Marketing Blog.

For more posts in related topic areas, see:

• Drug Safety
• DTC Advertising
• FDA
• Legal/Regulatory

If you wish to receive notice by email whenever a post is made to Pharma Marketing Blog, please subscribe.

The collection of articles and commentary in this first Pharma Marketing News Special Supplement dedicated to DTC advertising chronicles the emergence of issues and debates that have lead up to the industry's self-regulatory principles.

TABLE OF CONTENTS

Order both Volume One and Volume Two and SAVE! (Click Here)

Order and pay for Volume One now using your credit card

ONLY $29.95
PDF file delivered to you by email (usually within minutes of placing your order):

If you wish to be pay by check or credit card off-line, please use:
Printable Order Form